. Author manuscript; available in PMC: 2021 Oct 19.

Published in final edited form as: J Perinatol. 2021 Apr 19;41(6):1441–1447. doi: 10.1038/s41372-021-01054-1

Table 2:

Comparison of maximum serum creatinine values and acute kidney injury status as a function of patent ductus arteriosus management strategy

		PDA Management Strategy			p-value^*
	No PDA (N=369)	Conservative management (n=61)	Pharmacologic management (n=62)	Surgery (with or without pharmacologic treatment) (n=34)	p-value^*
Maximum Creatinine (mg/dL), mean ± SD	1 (0.6)	1.1 (0.4)	1 (0.3)	1.4 (1.1)	<0.0001
AKI Status
No AKI (n, %)	279 (75.6)	26 (42.6)	32 (51.6)	13 (38.2)	<0.0001
AKI (all) (n, %)	90 (24.4)	35 (57.4)	30 (48.4)	21 (61.8)
Stage (among AKIs)
Stage 1 (n, %)	49 (54.4)	18 (51.4)	11 (36.7)	7 (33.3)	0.11
Stage 2 (n, %)	18 (20.0)	12 (34.3)	13 (43.3)	7 (33.3)
Stage 3 (n, %)	23 (25.6)	5 (14.3)	6 (20.0)	7 (33.3)

PDA patent ductus arteriosus; AKI acute kidney injury

Estimated from an analysis of variance for maximum creatinine and a chi-square test for AKI status